Lindsay Robert, Cosman Felicia, Zhou Hua, Bostrom Mathias P, Shen Victor W, Cruz JoAnn D, Nieves Jeri W, Dempster David W
Clinical Research Center, New York State Department of Health, Helen Hayes Hospital, West Haverstraw, New York 10993, USA.
J Bone Miner Res. 2006 Mar;21(3):366-73. doi: 10.1359/JBMR.051109. Epub 2005 Nov 21.
We describe a quadruple tetracycline labeling method that allows longitudinal assessment of short-term changes in bone formation in a single biopsy. We show that 1 month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation.
Iliac crest biopsy, with histomorphometric evaluation, provides important information about cellular activity in bone. However, to obtain longitudinal information, repeat biopsies must be performed. In this study, we show the capability to obtain short-term longitudinal information on bone formation in a single biopsy using a novel, quadruple labeling technique.
Two tetracycline labels were administered using a standard 3 days on, 12 days off, 3 days on format. Four weeks later, the tetracycline labeling was repeated using the same schedule but with a different tetracycline that can be distinguished from the first by its color under fluorescent light. Iliac crest biopsies were performed 1 week later and prepared undecalcified for histomorphometry. Indices of bone formation 1 month apart were measured and calculated using the two sets of labels. We used this method to investigate the early effects of teriparatide [hPTH(1-34)] treatment on bone formation. The results were compared with those from a group of control subjects who were quadruple-labeled, but did not receive hPTH(1-34).
Treatment with hPTH(1-34) dramatically stimulated bone formation on cancellous and endocortical surfaces. This was achieved by both an increase in the linear rate of matrix apposition and extension of the bone-forming surface. New bone was deposited on previously quiescent surfaces (i.e., modeling-based formation), but a proportion of this could occur by encroachment from adjacent resorption cavities.
A single transiliac crest bone biopsy, after sequential administration of two sets of tetracycline labels is a useful approach to study the short-term effects of anabolic agents on human bone. One month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation.
我们描述了一种四重四环素标记方法,该方法能够在单次活检中对骨形成的短期变化进行纵向评估。我们发现,1个月的人甲状旁腺激素(1-34)[hPTH(1-34)]治疗可扩大骨形成表面,提高矿物质沉积率,并启动基于塑形的骨形成。
髂嵴活检及组织形态计量学评估可提供有关骨细胞活性的重要信息。然而,为了获得纵向信息,必须进行重复活检。在本研究中,我们展示了使用一种新型的四重标记技术在单次活检中获取骨形成短期纵向信息的能力。
采用标准的“3天给药、12天停药、3天给药”方案给予两种四环素标记物。四周后,按照相同方案重复四环素标记,但使用的是另一种四环素,在荧光灯下其颜色可与第一种区分开来。1周后进行髂嵴活检,并制备不脱钙的样本用于组织形态计量学分析。使用两组标记物测量并计算相隔1个月的骨形成指标。我们使用该方法研究特立帕肽[hPTH(1-34)]治疗对骨形成的早期影响。将结果与一组接受四重标记但未接受hPTH(1-34)的对照受试者的结果进行比较。
hPTH(1-34)治疗显著刺激了松质骨和骨内膜表面的骨形成。这是通过基质沉积线性速率的增加和骨形成表面的扩大实现的。新骨沉积在先前静止的表面(即基于塑形的骨形成),但其中一部分可能是由相邻吸收腔的侵蚀所致。
在依次给予两组四环素标记物后进行单次髂嵴骨活检,是研究合成代谢药物对人体骨骼短期影响的一种有用方法。1个月的hPTH(1-34)治疗可扩大骨形成表面,提高矿物质沉积率,并启动基于塑形的骨形成。